Galera Therapeutics, Inc.
GRTX
$0.0235
-$0.0004-1.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 11.74% | 62.97% | 80.38% | 75.26% | 65.49% |
| Total Depreciation and Amortization | -100.00% | -58.33% | -50.00% | -55.00% | 726.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.16% | 1.67% | -87.65% | -84.60% | -62.08% |
| Change in Net Operating Assets | 81.43% | 72.57% | -84.93% | -477.26% | -132.06% |
| Cash from Operations | 76.41% | 81.65% | 74.72% | 58.93% | 28.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 43.36% |
| Cash from Investing | -101.26% | -99.96% | -- | -- | 43.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,058.19% | -- | -- | -- | -108.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.31% | -3,079.22% | -96.17% | -122.37% | 27.08% |